<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Huang, Yu-Ting</dc:creator>
  <dc:creator>Lan, Qiang</dc:creator>
  <dc:creator>Lorusso, Girieca</dc:creator>
  <dc:creator>Duffey, Nathalie</dc:creator>
  <dc:creator>Rüegg, Curzio</dc:creator>
  <dc:date>2016-11-29</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Matricellular proteins play multiple roles in primary tumor growth, local invasion and  tumor angiogenesis. However, their contribution to metastasis and the putative  mechanisms involved are less well characterized. In ER-negative human breast  cancer, elevated expression levels of the matricellular protein Cysteine-rich angiogenic  inducer 61 (CYR61) are associated with more aggressive progression. Here, we  investigated the role of CYR61 in breast cancer lung metastasis using the triple  negative human breast cancer cell lines MDA-MB-231 and SUM159. Silencing of  CYR61 significantly decreased lung metastasis from tumors orthotopically implanted in  pre-irradiated or naive mammary tissue and upon tail vein injection. Constitutive  CYR61 silencing impaired cancer cell extravasation to the lung during the first 24 hours  after tail vein injection. In contrast, CYR61 inducible silencing starting 24 hours after  cancer cell injection had no impact on lung metastasis formation. In vitro experiments  revealed that CYR61 silencing decreased cancer cell transendothelial migration and  motility, reduced CYR61 levels present at the cell surface and sensitized cancer cells  to anoikis. Furthermore, we demonstrate that CYR61-dependent cell survival under  non-adhesive conditions relied, at least partially, on β1 integrin ligation and AMPKα  signaling while it was independent of AKT, FAK and ERK1/2 activation. Our data  provide the first evidence that CYR61 promotes breast cancer lung metastasis by  facilitating tumor cell extravasation and protecting from anoikis during initial seeding to  the lung. The uncovered CYR61-β1 integrin-AMPKα axis may serve as a potential  therapeutic target to prevent breast cancer metastasis to the lung.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/305539</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/305539/files/rue_mpc.pdf</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/305539/files/rue_mpc_sm.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.18632/oncotarget.13677</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>Oncotarget. - 2016, vol. 8, no. 6, p. 9200–9215</dc:source>
  <dc:subject>info:eu-repo/classification/udc/57</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">The matricellular protein CYR61 promotes breast cancer lung metastasis by facilitating tumor cell extravasation and suppressing anoikis</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
